Research programme: rho-associated protein kinase-2 inhibitors - HitGen

Drug Profile

Research programme: rho-associated protein kinase-2 inhibitors - HitGen

Alternative Names: ROCK2 inhibitors - HitGen

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HitGen
  • Class Antiglaucomas; Antihypertensives; Antineoplastics; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Glaucoma; Liver cancer; Non-small cell lung cancer; Pulmonary arterial hypertension

Most Recent Events

  • 02 Mar 2017 Rho-associated protein kinase-2 inhibitors - HitGen is available for licensing as of 02 Mar 2017. http://www.hitgen.com/?page_id=7107 (HitGen pipeline, March 2017)
  • 02 Mar 2017 early research in Glaucoma in China (PO) before March 2017 (HitGen pipeline, March 2017)
  • 02 Mar 2017 Early research in Liver cancer in China (PO) before March 2017 (HitGen pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top